Akers Biosciences OxiCheck Study Results Positive, Stock Up

Akers Biosciences Inc. (NASDAQ:AKER) recently announced favorable clinical results for its BreathScan OxiCheck disposable breath test. Following the news, shares surged 6.2% to close at $3.45 on Aug 19, 2016. We also note that shares are up a massive 185.1% on a year-to-date basis.

OxiChek, a part of the Akers’ Wellness product line, rapidly determines level of oxidative stress in the body by measuring the level of certain free radicals. Clinicians can employ the test to monitor and adjust their clients’ routine of nutritional supplementation in order to manage oxidative stress.

The test is also compatible with BreathScan Lync, the new Bluetooth-enabled reading device from Akers. This enables clinicians to monitor oxidative stress through the use of a mobile device.

As per a recent study, it was found that the correlation between OxiCheck and the standard reference laboratory blood testing method (TBARS) stands at 99.5%.

According to Akers “The study demonstrated a reproducibility of 100%, meaning the test results from the same lung simulator had zero variation after multiple repeats. The study further showed an intra-subject variation ranging from 1.61% to 14.87%, indicating a narrow variation upon multiple repeat tests by the same human subject.”

In late June, Akers signed an agreement with Aero-Med, a division of Cardinal Health (NYSE:CAH) , to distribute BreathScan OxiChek. Aero-Med is focused on penetrating the anti-aging, functional and integrative health and wellness treatment practitioner market in the U.S., which will drive Akers' top-line growth.

In fact, the company is expected to benefit from the growing adoption of rapid test devices in the near future. Akers plans to develop breathalyzers for determining asthma, chronic obstructive pulmonary disease and lung cancer.

Moreover, the company’s efforts to ramp up PIFA Heparin sales in the U.S. and overseas through new distribution partnerships are also encouraging.

In the recently concluded second quarter of 2016, product revenues surged 28.4%, on the back of massive China and U.S. sales for the PIFA Heparin test. The company sold about $880,000 PIFA Heparin tests, up 57% from the year-ago quarter.

Key Stocks

NuVasive (NASDAQ:NUVA) and Quidel (NASDAQ:QDEL) are two top-ranked stocks in the same space with a Zacks Rank #1 (Strong Buy).